Clinical Trial Update: A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma [Phase 1]

View source ↗

Summary

This clinical trial update documents a Phase 1 window-of-opportunity study of pembrolizumab in patients with resectable malignant pleural mesothelioma, which ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Chicago | Conditions: Pleural Mesothelioma | Phase 1 | Status: TERMINATED